Program
cotsiranib
Its studies are mostly in Cicatrix, Hypertrophic · Carcinoma, Basal Cell · Keloid · Carcinoma, Hepatocellular · Obesity, Abdominal, led by Sirnaomics.
Furthest: phase 2, since Oct 31, 201610 company-led studies, 1 open or runningNext primary completion: Jul 25, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sirnaomics | 101 open or running | phase 2since Oct 31, 2016 | Oct 31, 2016 | Jul 25, 2027phase 2 · NCT07677683 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 31, 2016First study: phase 2 study in Cicatrix, HypertrophicFirst studyNCT02956317 · 25 enrolled · United States
- Feb 26, 2020Phase 2 study in Bowen's DiseaseNCT04293679 · 25 enrolled · United States
- Dec 9, 2020Phase 2 study in Carcinoma, Basal CellNCT04669808 · 32 enrolled · United States
- Dec 15, 2020Phase 1 study in Carcinoma, HepatocellularNCT04676633 · 5 enrolled · United States
- Apr 8, 20212 phase 2 studiesNCT04844840, NCT04844983
- Dec 15, 2021Phase 2 study in Cicatrix, HypertrophicNCT05196373 · China
- Jun 8, 2022Phase 1 study in Obesity, AbdominalNCT05422378 · 8 enrolled · United States
- Jun 12, 2022Phase 2 study in Facial isSCCNCT05421013 · 9 enrolled · United States
- Jun 21, 2026Phase 2 study in Submental FullnessNCT07677683 · 30 planned · Australia
Ahead
- Jul 25, 2027Primary completion: phase 2 study in Submental FullnessNCT07677683
TargetBeta
PNP →read by rule
“A polypeptide nanoparticle (PNP)-based small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2), ”NCIt, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07677683Submental Fullness · Australia | 2 | Recruiting | Jul 25, 2027 | 30 |
| NCT05421013Facial isSCC · United States | 2 | Terminated | Mar 29, 2023 | 9 |
| NCT05422378Obesity, Abdominal · United States | 1 | Completed | Feb 3, 2023 | 8 |
| NCT05196373Cicatrix, Hypertrophic · China | 2 | Withdrawn | Jun 30, 2022 | 0 |
| NCT04844983Squamous Intraepithelial Lesions · United States | 2 | Completed | Aug 24, 2022 | 44 |
| NCT04844840Keloid · United States | 2 | Completed | May 17, 2023 | 29 |
| NCT04676633Carcinoma, Hepatocellular · United States | 1 | Completed | Jan 13, 2023 | 5 |
| NCT04669808Carcinoma, Basal Cell · United States | 2 | Completed | Feb 9, 2023 | 32 |
| NCT04293679Bowen's Disease · United States | 2 | Completed | Oct 21, 2020 | 25 |
| NCT02956317Cicatrix, Hypertrophic · United States | 2 | Completed | Jan 2018 | 25 |
How it is read
Names in the registry
- “STP705”, 10 entries
Conditions, from the studies’ own filings
- Cicatrix, Hypertrophic, 2 studies
- Carcinoma, Basal Cell, 1 study
- Keloid, 1 study
- Carcinoma, Hepatocellular, 1 study
- Obesity, Abdominal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.